本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Intra-Cellular Therapies Inc.

131.87
0.0000
成交量:- -
成交額:21.18億
市值:140.21億
市盈率:-182.12
高:131.87
開:131.87
低:131.87
收:131.87
52周最高:131.98
52周最低:64.09
股本:1.06億
流通股本:1.05億
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-0.7241
每股收益(LYR):-0.7241
淨資產收益率:-8.58%
總資產收益率:-6.96%
市淨率:12.21
市盈率(LYR):-182.12

資料載入中...

2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2025/04/02

重要事件披露

Form 8-K - Current report
2025/04/02

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2025/03/27

重要事件披露

Form 8-K - Current report
2025/03/20

[修訂]年度報告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2025/03/18

重要事件披露

Form 8-K - Current report
2025/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/03

重要事件披露

Form 8-K - Current report
2025/02/21

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/21

重要事件披露

Form 8-K - Current report
2025/01/13

重要事件披露

Form 8-K - Current report
2025/01/10

重要事件披露

Form 8-K - Current report
2024/12/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/12/04

關聯方擬減持公告

Form 144 - Report of proposed sale of securities